Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial

Drug Metab Rev. 2021 Feb;53(1):141-170. doi: 10.1080/03602532.2020.1845201. Epub 2020 Nov 23.

Abstract

The global spread of the novel coronavirus (SARS-CoV-2) and increasing rate of mortality among different countries has raised the global concern regarding this disease. This illness is able to infect human beings through person-to-person contact at an extremely high rate. World Health Organization proclaimed that COVID-19 disease is known as the sixth public health emergency of international concern (30 January 2020) and also as one pandemic (12 March 2020). Owing to the rapid outbreak of COVID-19 worldwide, health authorities focused on discovery of effective prevention and treatment techniques for this novel virus. To date, an effective drug for reliable treatment of COVID-19 has not been registered or introduced to the international community. This review aims to provide recently presented techniques and protocols for efficient treatment of COVID-19 and investigate its morphology and treatment/prevention approaches, among which usage of antiviral drugs, anti-malarial drugs, corticosteroids, and traditional medicines, biotechnological drugs (e.g. combination of HCQ and azithromycin, remdesivir, interferons, novaferon, interferon-alpha-1b, thymosin, and monoclonal antibodies) can be mentioned.

Keywords: COVID-19; SARS-CoV-2; antiviral drugs; coronavirus; viruses.

Publication types

  • Review

MeSH terms

  • Antiviral Agents* / classification
  • Antiviral Agents* / pharmacology
  • COVID-19 Drug Treatment*
  • Drug Therapy, Combination / methods
  • Humans
  • Medication Therapy Management
  • SARS-CoV-2

Substances

  • Antiviral Agents